Evan Lippman
Known title: EVP, Business DevelopmentCIK: 0002062834
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▼ Sell | Open Market | 18,600 | $680K | 8/17/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 11,841 | — | 5/14/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 5,746 | $204K | 5/14/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 74,008 | — | 5/14/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 35,912 | $1.3M | 5/14/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.